UK approves J&J psoriasis pill as talks over DePuy spin-off collapse
The UK approved J&J's Icotyde psoriasis pill. Talks on spinning off DePuy Synthes collapsed over a leadership dispute, sources said.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, UK regulators approved Icotyde, an oral psoriasis treatment from Johnson & Johnson, for patients aged 12 and older weighing at least 40 kg. The approval rests on four Phase 3 trials involving roughly 2,500 patients. The company is also studying icotrokinra for other inflammatory diseases, and peak sales for the drug are estimated at about $5 billion.
J&J plans to separate its orthopedics business as DePuy Synthes around mid-2027. Private equity interest and market chatter put the unit's value near $20–22 billion, but no deal has been finalized. Sources say the parties had reached an advanced agreement on key terms and structure, yet talks broke down at the last minute over a leadership dispute.
why it matters
The UK approval widens the commercial reach of a new drug and reinforces the company's push into immunology. For investors, the bigger question is the DePuy Synthes separation: without a signed deal the unit's valuation remains speculative, and the collapse of talks leaves timing and structure unclear.
market impact
J&J shares: the new drug strengthens the pipeline, while the collapsed DePuy talks add uncertainty to valuation.
tags
instruments
sources
- Key facts: JNJ Icotyde OK UK; DePuy spin $20–22B; talks collapse over leadership — TradingView, 24 October 2026 at 07:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗